Sage’s dalzanemdor miss in Alzheimer’s trial
Sage Therapeutics’ share price fell 11% to $6 in pre-market activity on Tuesday, after it announced disappointing top-line results from LIGHTWAVE, a 12-week, Phase II randomized, double-blind, placebo-controlled study to evaluate the effects of dalzanemdor (SAGE-718) in participants with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease (AD).
SAGE's Dalzanemdor Fails to Meet Goal in Alzheimer's Disease Study
The phase II LIGHTWAVE study evaluating Sage Therapeutics' dalzanemdor for treating cognitive issues due to Alzheimer's disease fails to meet the primary goal.
After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study
Sage Therapeutics' dalzanemdor failed to show significant results in Phase 2 Alzheimer's study. The company discontinues Alzheimer's development but expects Huntington's data soon. Stock drops 10.7%.
Sage Therapeutics Stock Plunges on Disappointing Study Results for Alzheimer’s Treatment
The biopharmaceutical company isn’t planning further clinical development of dalzanemdor to treat Alzheimer’s.
Sage Therapeutics Ends Development of Dalzanemdor in Alzheimer's Disease
Sage Therapeutics does not plan further clinical development of its dalzanemdor drug candidate in Alzheimer's disease following its failure in a mid-stage study.
Sage Therapeutics: With Dalzanemdor As The Last Lifeline, Not Much Hope Left
Sage Therapeutics is a sell due to failure of SAGE-324 in essential tremors and dalzanemdor's poor performance in Parkinson's Disease. Read more on SAGE stock here.
Sage Therapeutics scraps Alzheimer’s drug development after trial fails; shares slide
Sage Therapeutics said on Tuesday it would stop developing its experimental drug, dalzanemdor, for Alzheimer's disease after it failed to meet the main goal of a late-stage trial, sending its shares down 10% in premarket trading.
Sage Therapeutics stock drops after disappointing Alzheimer's trial results
Sage Therapeutics shares fell as much as 25% in premarket trading after the company announced disappointing topline results from its Phase 2 LIGHTWAVE study of dalzanemdor (SAGE-718) for the treatment of mild cognitive
FierceBiotech1d
Sage scraps Alzheimer's program as dalzanemdor goes 0 for 2, leaving hopes resting on Huntington's
Sage Therapeutics has seen another clinical trial go up in smoke. | Sage Therapeutics has seen another clinical trial go up ...
pharmaphorum13h
Sage takes another hit as Alzheimer's drug is canned
Sage Therapeutics has said it will stop the development of dalzanemdor in Alzheimer's disease, a few months after pulling the ...
BioSpace1d
Sage Suffers Third Neuro Stumble in Six Months With Disappointing Mid-Stage Alzheimer’s Readout
Sage has decided to discontinue the development of dalzanemdor in Alzheimer’s disease. A study of the candidate in Huntington ...
SAGE Therapeutics: Hold Rating Amid Clinical Setbacks and Narrowed Success Prospects
SAGE Therapeutics (SAGE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Douglas ...
Sage Therapeutics’ stock slides after biotech says it will cease development of Alzheimer’s treatment
Sage Therapeutics Inc.’s stock tumbled 12.8% early Tuesday, after the company said a mid-stage trial of a treatment for mild ...